Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is reasonably priced on P/E.
Target Price
The average target price of SANN.SW is 30 and suggests 91% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre